#Danco

[nichimgriff]

Kevin: and no bullshit!

Nico: Bullshit? That's my cue! *nom*

[polarpics]

[ecarchive]

27.3.2023

[texasflycaster]

The Gifts Keep on Giving

Fly Fishing Father’s Day List Continues – 2024 Guide for under $500 Giving We have had our look for 2024, at the Father’s Day Fly Fishing Gift Guide SUB $100, and now it is time to kick it up a notch, because you know he is the dude, and the dude abides. I try and cover a variety of tastebuds, from hard blasting coffee in the field. YETI 64 French Press  – Just because good coffee can make a…

[troythecatfish]

[nopickls]

The heroic age of Antarctic exploration - after The Terror opening credits

[incesthemes]

belgica crew getting depressed over not being able to have sex while stuck in the pack, meanwhile cook and amundsen are fine and immune to polar night depression on account of having reinvented homosexuality

[sunlaire]

I NEED a Belgica show, I need for more people to be unwell about danco and lecointe with me pleeeease

[justinspoliticalcorner]

Chris Geidner at Law Dork:

The future of mifepristone access is up in the air on multiple fronts right now — just five months after the U.S. Supreme Court rejected a challenge to the U.S. Food and Drug Administration’s treatment of the medication abortion drug.

In June, a unanimous Supreme Court held that the private plaintiffs challenging the FDA’s rules surrounding mifepristone access lacked standing to bring their claims. At that point, the challenges had already been whittled down. They were not to the original approval of mifepristone itself but to the 2016-and-since changes to access of the drug, including allowing the mailing of the drug by ending the in-person dispensing requirement and increasing the gestational limits on when mifepristone can be used. Now, though, Donald Trump has won election to the presidency — and questions about what his new administration will do to federal policy surrounding the drug are front and center. Additionally, moves in recent weeks in existing litigation suggest that neither backers of the drug’s availability nor those seeking to restrict its access are willing to sit back and wait for the Trump administration to act. The result could be a flurry of litigation in the coming months, some all but forcing the Trump administration to quickly weigh in on the matter and, potentially, sending one or more questions back to the Supreme Court sooner rather than later.

Relevant to the mifepristone litigation, Trump has announced that former Florida Attorney General Pam Bondi is his nominee for attorney general, Robert F. Kennedy Jr. is his nominee to run the Department of Health and Human Services, and Marty Makary is his nominee to run the FDA. Since the election, anti-abortion groups and activists have been “emboldened,” as The Washington Post reported, despite abortion protections passing almost everywhere they were on the ballot. There will be efforts to push the administration to adopt anti-abortion positions, but, beyond that, those same groups will be going to court regardless of what the new administration does. Although far-right groups like Project 2025 were advocating for a Trump administration to resurrect and use the 1873 Comstock Act to prevent mailing of mifepristone (and, potentially, any other “article or thing” used in an abortion, under reasoning I described in this article), neither Trump nor any of these key nominees have backed such a step. Although Bondi certainly identifies as “pro-life,” the primary case cited from her time as Florida attorney general is her 2016 defense of a Florida law requiring a 24-hour waiting period before a woman or other pregnant person could get an abortion. It is important to remember that she left office more than three years before Roe v. Wade was overturned. As such, limits in her arguments in the case don’t tell us — in either direction — what her views would be today.

[...]

Missouri, Kansas, and Idaho — the trio of states — filed a motion on Oct. 11 to amend their complaint in the case, basically, to add to it in light of new information and in the wake of the Supreme Court’s standing ruling. On Nov. 1, however, the Justice Department filed a motion to dismiss the case, as well as a memorandum of law supporting that and opposing the states’ request to amend their complaint because, the lawyers wrote, “Once Plaintiffs’ Complaint is dismissed, the separate Complaint filed by the three Intervenor States—the States of Missouri, Idaho, and Kansas (“the States”)—must likewise be dismissed. The Fifth Circuit has squarely held that intervention requires a jurisdictionally proper suit. Because this Court never had jurisdiction over Plaintiffs’ claims, it could not obtain jurisdiction over the States’ claims.“ Danco Laboratories, the maker of Mifiprex, filed a similar motion and argument.

[...]

Most important to all of this is what happens if Kacsmaryk rejects DOJ’s request or does not rule by Jan. 20. At that point, although Danco’s position isn’t likely to change, it is possible that DOJ and the FDA’s position in the case could change. If not dismissed by Jan. 20, then, it is very possible that this case could force the new Trump administration to very quickly weigh in on these questions about mifepristone access. Remarkably, that is not all. In a less closely watched case, a group of Democratic-led states sued the FDA in Washington to protect — and, in fact, expand — access to mifepristone. The case had been in a holding pattern while some Republican-led states unsuccessfully sought to intervene in the case, but it recently got going again. The Democratic-led states filed their motion for summary judgment in October, arguing that mifepristone should not be subject to “special restrictions” when “[i]t is even safer than such well-known drugs as Tylenol, Viagra, and insulin” that have no such restrictions.

[...] Most important to all of this is what happens if Kacsmaryk rejects DOJ’s request or does not rule by Jan. 20. At that point, although Danco’s position isn’t likely to change, it is possible that DOJ and the FDA’s position in the case could change. If not dismissed by Jan. 20, then, it is very possible that this case could force the new Trump administration to very quickly weigh in on these questions about mifepristone access. Remarkably, that is not all. In a less closely watched case, a group of Democratic-led states sued the FDA in Washington to protect — and, in fact, expand — access to mifepristone. The case had been in a holding pattern while some Republican-led states unsuccessfully sought to intervene in the case, but it recently got going again. The Democratic-led states filed their motion for summary judgment in October, arguing that mifepristone should not be subject to “special restrictions” when “[i]t is even safer than such well-known drugs as Tylenol, Viagra, and insulin” that have no such restrictions.

With Trump's win, the future of mifepristone could be more decisively settled this SCOTUS term or the next one.

[amundsenxcook]

i am pissing shitting crying banging my fists against the walls

[johntorrington]

girls when they get spoiled for the 130 year old historical event they’ve been reading about

[nichimgriff]

[polarpics]

[nichimgriff]

[morsking]

harry at the bookstore: i don’t feel like i have any kids

me, who knows:

[captainmikesfishingadventures]

Apologies for the Delayed Fishing Report: ICAST Adventures and Quality Time

I want to apologize as I do not have a current fishing report. If you follow the link you can read about what we have been up to and why we haven't been fishing! I think you will enjoy the story. Have a blessed week my friends. Tight Lines and Good times!